Compare DexCom, Inc. (DXCM) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Otis Worldwide Corp — how do they compare? DexCom, Inc. trades at $91 (market cap $33.79B), while Otis Worldwide Corp trades at $73.93 (market cap $27.80B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.41% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | OTIS | |
|---|---|---|
Market Cap | $33.79B | $27.80B |
Sector | Health | Industrials |
52-Week High | $89.53 | $93.62 |
52-Week Low | $54.84 | $69.34 |
Enterprise Value | $33.24B | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Otis Worldwide (OTIS) trades at $73.58, up 0.97% on the day, with a neutral technical signal. The company reported mixed Q2 2026 results, beating revenue estimates but missing EPS expectations and cutting full-year profit guidance due to margin pressures. Strong service segment growth, particularly in modernization, contrasts with weak new equipment demand. Analyst consensus is divided with a $92.50 price target, suggesting significant upside from current levels.
The outlook balances service-driven revenue momentum against near-term margin headwinds. Investment opportunity lies in Otis's defensive service business and global market leadership, but risks include execution on margin improvement, China exposure, and competitive pressures. Cash flow volatility and high debt levels require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
